Kymera Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
KYMR$136.64-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except for share and per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Collaboration revenue | $34,365 | $22,100 |
| Operating expenses: | ||
| Research and development | $98,162 | $80,255 |
| General and administrative | 20,357 | 16,271 |
| Total operating expenses | 118,519 | 96,526 |
| Loss from operations | (84,154) | (74,426) |
| Other income (expense): | ||
| Interest and other income | 14,981 | 8,917 |
| Interest and other expense | (61) | (72) |
| Total other income: | 14,920 | 8,845 |
| Net loss | $(69,234) | $(65,581) |
| Other comprehensive loss: | ||
| Unrealized (loss) gain on marketable securities | (5,994) | 1,427 |
| Total comprehensive loss | $(75,228) | $(64,154) |
| Net loss | $(69,234) | $(65,581) |
| Net loss per share, basic and diluted | $(0.71) | $(0.82) |
| Weighted average common stock outstanding, basic and diluted | 97,534,269 | 80,146,531 |
CONDENSED CONSOLIDATED STATEMENTS OF
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.